Filing Details
- Accession Number:
- 0001209191-19-053497
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-10-17 18:59:43
- Reporting Period:
- 2019-10-15
- Accepted Time:
- 2019-10-17 18:59:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 906709 | Nektar Therapeutics | NKTR | Pharmaceutical Preparations (2834) | 943134940 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1394875 | M Gil Labrucherie | C/O Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco CA 94158 | Svp, Coo & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-10-15 | 25,000 | $7.21 | 252,872 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-10-15 | 25,000 | $15.83 | 227,872 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Disposition | 2019-10-15 | 25,000 | $0.00 | 25,000 | $7.21 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 25,000 | 2016-02-08 | 2020-02-07 | No | 4 | M | Direct |
Footnotes
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020.
- This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
Billionaire Hedge Funds
